SCHEMBL6324752

SCHEMBL6324752

Cc1cc(CC(=O)N2CCC(N3CCCC3)CC2)c(/C=C2\C(=O)Nc3cccc(-c4ccccc4F)c32)[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 3/20 0.44
CCR3 P51677 6/20 0.40
KDR P35968 4/20 0.38
ALK Q9UM73 4/20 0.38
CSF1R P07333 2/20 0.38
RET P07949 2/20 0.38
FGFR1 P11362 2/20 0.38
SRC P12931 2/20 0.38
FGFR3 P22607 2/20 0.38
MAPK1 P28482 2/20 0.38
FLT4 P35916 2/20 0.38
FLT3 P36888 2/20 0.38
PDGFRB P09619 2/20 0.38
KIT P10721 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
CYP2D6 P10635 2/20 0.38
CYP2C19 P33261 2/20 0.38
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6322518 0.90 FLT1 (0.41) FLT1CCR3KDRALKCSF1R
SCHEMBL6327454 0.88 FLT1 (0.47) FLT1KDRALKCSF1RRET
SCHEMBL6322071 0.87 FLT1 (0.47) FLT1KDRALKCSF1RRET
SCHEMBL6323877 0.87 KDR (0.44) FLT1KDRALKCSF1RRET
SCHEMBL6320496 0.85 FLT1 (0.46) FLT1KDRALKCSF1RRET
SCHEMBL6327802 0.82 KDR (0.43) FLT1KDRALKCSF1RRET
SCHEMBL6329410 0.80 PDGFRB (0.49) FLT1KDRALKCSF1RFGFR1
SCHEMBL6321232 0.80 FLT1 (0.44) FLT1KDRALKCSF1RRET
SCHEMBL6321553 0.79 KDR (0.41) FLT1KDRALKCSF1RRET
SCHEMBL6329837 0.78 KDR (0.42) FLT1KDRALKCSF1RRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 FLT1 1811/4885CCR3 3961/4885KDR 819/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 FLT1 1811/4885CCR3 3961/4885KDR 819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.